INNSPUB

International Journal of Biosciences | IJB |
ISSN: 2220-6655 (Print), 2222-5234 (Online)
http://www.innspub.net
Vol. 16, No. 4, p. 331-344, 2020

REVIEW PAPER OPEN ACCESS

Nanocrystals: A review

B. Nitish, K. Pavithra, Singam Malathi, Khilifa Fathelrahman Khalifa Abdelmagid, S. Jeganath*

Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India

Key words: Clinical trials, Nanocrystals, Nanomedicine, Nanoparticles, Nanotherapeutics, Translational medicine.

http://dx.doi.org/10.12692/ijb/16.4.331-344 Article published on April 29, 2020

Abstract

Nanotechnology in many relevant fields, like medicine and pharmacy, can impact our lives enormously over the next decade. Transfer of substances into the nano dimension improves their physical characteristics that have been used in pharmaceutics to create a new revolutionary formulating method for poorly soluble drugs: nanocrystals for medicines. The nanocrystals of drugs are not part of the future; the first drugs are still in the marketplace. Commercially applicable processing techniques, pearl milling, and homogenization by high pressure are checked. This addresses the mechanics behind the product nanocrystals and improvements in their physical properties. Poorly soluble small molecules usually pose translational obstacles due to their poor solubility, poor bioavailability and difficulties in formulating. Nano crystallization is a flexible process with the added advantage of a provider-free delivery method to save poorly soluble drugs. We include a thorough overview of nanocrystals in this study, including a focus on their clinical interpretation. The study also shines a light on medically authorized nanocrystal medicinal items including those under production.

* **Corresponding Author:** S. Jeganath ✉ jeganaths@gmail.com

Introduction

Nanotechnology currently is found all over our everyday lives. If it's in microprocessor development (in which a need to incorporate multiple microprocessors per square millimeter is obvious to generate more computing-powered chips) (Kanellos M. *et al.,* 2005). The the field of biotech (in which new techniques are required to communicate efficiently with proteins of ever decreasing sizes (Merkle RC *et al.,* 199), or literally cosmetics science and products (where nanonized substances could provide a wide spectrum of benefits (Müller RH *et al.,* 2006). This need for ever decreasing volume is normal in these areas. A vital aspect is the nanonization of products, either for surgical use (e.g., mini robots) to clear arteries (Kazimierski P *et al.,* 2005) and in a pharmaceutical industry (e.g., nanoencapsulated vitamins of organic foods, or the use of medicinal drugs (Velikov K *et al.,* 2006) both economically and pharmaceutically. Since the very first writing-through paper (in Microencapsulated ink was used as a thin film on both the back of the top sheet and the typewriter force removed the caps to pass the fluid to the bottom sheet (Cinzia De Vita VC *et al.,* 2004). Nanotechnology has contributed to making advances surrounding. In medical application this review may concentrate on nanosized crystals. The ability to nanonize (i.e. to minimize the volume to under 1000 nm) is among the primary factors for current drug therapy in drug delivery and medical implementations, now and into the future years.

The amount of poorly soluble drugs has already been gradually rising over the last ten years. Estimates suggest that 40 per cent of pipeline products had issues with solubility (Speiser PP *et al.,* 1998). Development in high-performance detection techniques contributes to a wider range of previously unknown medicines that are poorly soluble in water. Theology notes which approximately 60 per cent of all medicines that come straight from metabolism are actually poorly soluble (Merisko-Liversidge E *et al.,* 2002). Low water-solubility coincides with low bioavailability.Unless there is no way of boosting drug solubility it won't even be able to be consumed in to the blood circulation from the digestive tract to enter the building of action.

Many poorly soluble medications can be solubilized in several ways. Yet such approaches are restricted to medicines with these kind of characteristics in terms of their composition r, for example, their molecular size or conformation (Grau MJ *et al.,* 2000). In addition, the use of surfactants or cosolvents is technically possible, but also leads to improved harmful effects (e.g., Cremophor EL (BASF, Ludwigshafen, Germany) and increases the susceptibility of Taxol and HP-β-cyclodextrin causes itraconazole nephrotoxicity in Sporanox ® (Willems L *et al.,* 2001) as well as other drawbacks (e.g. organic solvent residues). To raise the contact area and therefore the speed of degradation, micronization of pharmaceutical powders to sizes between 1 and 10 μm is also not necessary to solve the intestinal absorption concerns of several Biopharmaceutical Design Class II drugs that are very poorly soluble. The transition towards micronization to nanonization was a subsequent phase. Well before the beginning of the 90s, Elan Nanosystems (San Francisco, CA, USA) has propagated the use of nanocrystals rather than microcrystals for both progressing oral bioavailability, as well as using liquid condensed nanocrystals (nanosuspensions) for intravenous or pulmonary medication distribution.

Nanocrystals

Drug nanocrystals were nanometer-scale crystals, meaning crystalline nanoparticles were formed. Controversies are taking place on the concept of a nanoparticle, meaning the size of a particle to be defined as a nanoparticle depending on a specialty, e.g. samples of fluid science are sometimes labeled as nanoparticles as they are smaller than 100 nm or often smaller than 20 nm. Depending on the size of the plant, nanoparticles in the medicine sector should be considered as having a length of about several nm and 1000 nm (= 1 μm); thus, microparticles are 1–1000 μm in size.A further attribute tends to have been that medicine nanocrystals are constructed of 100 percent content; as with polymer nanoparticles, there

is really no material to bear. Availability of drug nanocrystals into fluid materials ends in so-called "nanosuspensions" (as opposed to "microsuspensions" or "macrosuspensions"). Typically the dispersed molecules have to be protected by surfactants or polymeric stabilizers, for instance. The dispersing factors can well be air, aqueous solutions, or non-aqueous media (e.g., liquid polyethylene glycol [PEG], oils).

The drug microcrystal processing to drug nanoparticles may result in a crystalline or undifferentiated content, especially where precipitation is introduced, fluctuates depending on the production technological. An amorphous powder nanoparticle should not be called nanocrystal in the truest sense. Throughout the years, nanoparticles (NPs) derived from organic and inorganic compounds have also been developed to overcome physiological barriers and to provide medicines for a range of indications(De Jong WH etal 2008; Bae YH *et al.,* 2011) Water-insoluble or hydrophobic medicines gain financially in order to ensure optimum bioavailability and thus sufficient efficacy (Muller RH *et al.,* 2004). As reported in 2015, 40 percent of drugs on the market and 90 percent of drugs in the research pipeline are experiencing soluble problems (Sonvico F *et al.,* 2005). These figures refer as a consequence of endogenous anhydrous solutions to 40 per cent of all possible product targets (Savjani KT *et al.,* 2012). In comparison, only a handful of hydrophobic medicinal products need scientifically relevant vectors, which may be suitable for treatments (Anselmo AC *et al.,* 2014).

Both for objectives of this review of the literature, drug nanocrystals may be categorized as small, solid particles with quite an average size < 1 μm as well as a crystalline attribute.

The system offers an extraordinary capacity for providing hydrophobic drugs. Its importance stems from the fact that nanocrystals are made completely from a 100 % drug or even the target thus eliminating ancillary function for a carrier (Junghanns J *et al.,* 2008). Alternatively, to stabilize crystal dispersions, surfactants or stabilizers are commonly used for liquid media.

Nanocrystalline pharmaceutical processing increases hydrophobic drug solubility leading to an improvement in the average volume ratio and increased nanosizing-related degradation rates. (i.e., dissolution rate) (Tuomela A *et al.,* 2016). Drug crystals are especially ideal for the recovery of medications considered ineffective in the Class II and IV Biopharmaceutical Classification System (BCS) (US Department of Health and Human Services *et al.,* 2017).

The BCS grading system is an analytical method that under specified conditions it assesses the permeability and solubility. That approach splits up their medications into two separate groups. Whereas Class I drugs are highly soluble and highly permeable, Class II molecules are poorly soluble and highly permeable, Class III is highly soluble and poorly permeable, with poor solubility and low durability of Class IV drugs.

Nanocrystal formulations have also proven soluble in suspensions and are often associated with dispersions of colloidal nanocrystals (NCDs). The dispersions provide a platform through rendering highly stable and commercially viable products simple to scaled up and manufacture. These criteria for propagation or scale-up have also been extensively discussed elsewhere (Pawar VK *et al.,* 2014; George J *et al.,* 2015). The widely used propagation methods include the use of microfluidic systems or the flexible and customizable milling process (Wang X, 2005; Boleininger J 2006; Van Eerdenbrugh B 2008; Peltonen L 2010; Lu Y 2015; Malamatari M 2018.).

Via the method of implementing nanocrystals a few hydrophobic drugs were salvaged. The medications have already been developed and approved successfully by the FDA to treat a range of health conditions ranging from dental disorders to cancer (Merisko-Liversidge E 2011; Chen H 2011; Brough C

2013; Möschwitzer JP 2013; Gao L 2013; Kalepu S 2015; Lee BK 2015; Lu Y 2016; Miao X 2017; Peltonen L 2018). The approved medications can be administered through various routes, particularly oral, dermal, and parenteral, based on the condition. It illustrates exactly how powerful a drug system with nanocrystal is previous to this, information on pharmacokinetics, bio-distribution, and pharmacokinetics for organs engaged in transmission pathways examined utilizing nanocrystal technology were also extensively addressed (Shegokar R 2010; He Y, 2015; Su H 2018, Lu PS 2018, Maudens P 2018, and Koshani R 2018). Reviews also addresses the biodistribution process of nanocrystal drugs in blood, skin, liver, spleen, lung, kidney, tumor, and thymus (i.e., organs involved in inspection / liquidity, and immune responses) (Lu Y 2017). Several articles are already being published explaining the techniques utilized solely for the processing of nanocrystal medicinal products; the type of stabilizers or surfactants concerned; and the lessons learned about them (Möschwitzer JP *et al.,* 2013; Mura S *et al.,* 2013).There is a wide translational difference between another hugely exciting device and its medical recognition. In the study, we discuss the pharmaceutical nanocrystal development from either a translational perspective, and its development. Given the obvious benefits of the program, people are talking about the absence of products approved by FDA. Discussing the challenges involved in successful incorporation into the system.

Properties of nanocrystals

The key reasons for both higher breakdown speed and, ultimately, increased bioavailability are: Increase in dissolution rate by extension of surface area: The reduction in size contributes to an enhanced total area and therefore to a ballistic coefficient of breakdown as per the Noyes-Whitney equation (Noyes A, Whitney W 1897). Hence micronization is also an effective way to effectively improve the bioavailability of medicines in which the speed restricting phase was the breakdown speed. The sample layer has been further expanded by shifting through micronization to nanonization and thus the rate of breakup improves also. In many other situations a higher speed of breakdown is associated with such a higher solubility in saturated Increase in saturation solubility: The common assumption in the manual was that the chemical composition of saturated cs is a constant based on the material, the separation environment and temperature. That's true for everyday life powders having a size in or above the micrometer scale. Nevertheless, the concentration viscosity often depends on both the particle size under a crucial size of 1–2 μm. It decreases with much less than 1000 nm of particulate matter. Chemical nanocrystals however exhibit an improved viscosity in saturated. It comes with couple of benefits:

First, the level of velocity is further improved as dc / dt is proportional to the concentration of gradient (cs–cx)/h (cs- saturation solubility, cx - bulk concentration, h - diffusional distance).

Second, because of the enhanced permeability of saturation, the concentration gradient among gut lumen and blood is enhanced and thus the penetration by passive diffusion is enhanced.

The vapor pressure of lipid droplets in such a gas phase (aerosol) enhances through enhanced ground thickness that implies rising particle size, as per the Kelvin equation (Anger S 2005). Increasing fluid has its specific substance dielectric constant, and the liquid compression improvement would have been determined by both the compound-specific vapor pressure accessible. The situation of molecular transformation from either a liquid state to a gas phase is essentially identical to that of molecular transition from either a solid state (nanocrystal) to a liquid state (medium of dispersion). That intensity of vapour is equal to the stress of destruction. There is indeed a mixture of disintegrating substances in the condition of saturated bioavailability, and recrystallizing substances.

In case the breakdown stress improves and the chemical composition of dissolution reduces, this optimum could be changed. Within normal

circumstances (micrometer droplet size), increasing drug crystal does have a similar micrometer-sized dissolve stress, equivalent to fluids with similar dielectric constant. Displays the improvement of cs for the poorly soluble $BaSO_4$ salt measured utilizing Kelvin equation.

Advantages of an amorphous particle state: Undifferentiated medicines are very well established to have a higher solubility in concentration comparison to crystal medicine content. Chloramphenicol palmitate is a prime example of this study. The polymorphic alteration I has a solubility of 0.13, the high-energy modification II does have a viscosity of 0.43 and the amorphous substance has a solubility of 1.6 mg / ml (Hancock BC *et al.,* 2000; Chong-Hui G *et al.,* 2001).

This applies to nanoparticles used in medicines. Undifferentiated drug nanoparticles have greater solubility in saturated similar to crystal-state medicine nanocrystals of similar duration. Hence a mixture of nanometer size or undifferentiated phase is suitable for reaching the highest concentration soluble improvement.

Moreover, a condition to be used in pharmaceuticals would be that the undifferentiated condition could be preserved for both the consumer's lifespan. Passing so many information to medicine nanocrystals indicates which ideal medicine nanoparticles with both the maximum improvement in penetration viscosity ought to be e.g. 50 nm or 20–30 nm, and amorphous. Of necessity, it should be taken into account that blood makeup is expected with some kind of medicine In several situations it is not preferred to dissolve too quickly (development of large plasma peaks, decrease of t max).

There's a need to incorporate product nanocrystals with conventional sustained release technologies (e.g., coated pellets) for several purposes to prevent rapid degradation, exceptionally high plasma increases and excessive t-max, and also to achieve sustained plasma rates. To summarize, the ideal nanocrystal volume and crystal / undifferentiated condition of both the medicine would depending on:

Blood profile needed.
Route to administration.
Stability of the amorphous state during product shelf-life.

The level should be as small as possible in the situation of IV-nanocrystals, should the binding affinities of a substance be reproduced. Unless the purpose would be to (e.g., the brain using Path Finder TM technology (Müller RH *et al.,* 1998) or any other organs / tissues), their drug nanocrystals ought to have the volume to postpone the degradation and provide them with an opportunity to reach its blood-brain barrier (BBB) towards BBB target endothelial body cells or some other target (Kreuter J *et al.,* 1995).

Production of nanocrystals

Nanocrystals can be generated in various ways in the desired shape and size. In general, three concepts can be used: milling, methods of precipitation and methods of homogenisation, and also a variation both. Topdown techniques are the industrially applicable approaches, i.e. beginning from a huge-sized medicine product to be scaled down. Bottom up innovations (i.e., beginning from a dispersed molecule, precipitation) are not presently used for the manufacture of consumer goods, to our understanding. Justifications can include the desire to actually extract solvents, the challenge in managing the system, and the reality that so many poorly soluble drugs are not only poorly soluble in aqueous but organic media as well.

Precipation method: Among the first measures of precipitation is the hydrosol formulation that Sucker created, with both the intellectual property owned by Sandoz (Gassmann P*et al* 1994; List MA, Sucker H 1988). The technique is essentially a method of traditional precipitation, recognized as "via humida paratum" (VHP). The VHP. The method for the preparation of ointments including fine distributed,

catalyzed medicines was defined in the old pharmacopeia. Nevertheless, the product needs to be dismantled in at least one solvent which causes problems in both aqueous and organic media for new, insoluble, creative drugs. There are a few explanations that this innovation have not yet been implemented to a material, to our understanding.

Further process of precipitation is the processing of undifferentiated medicinal nanoparticles like carotene nanoparticles in the food industry (Shackleford DM *et al.,* 2003) eg, Lucarotin ® or Lucantin ® (BASF). At a given temperature, a carotenoid solution and a surfactant in a digestible oil are combined with a suitable solvent.A safe colloid is applied to arrive at the solution. That results in a two-phase O / W system. In the oily process, the colloid-stabilized carotenoid localizes. X-ray analyzes after lyophilization reveal that about 90 per cent of the carotenoid is in an amorphous state. Soliqs uses this technique for pharmaceuticals, and advertises it underneath the trade name NanoMorph ®.

Milling method: Standard NanoCrystals ® method uses a beads or a pear mill to accomplish reduction in particle size. Ball mills have already been recognized for both the development of ultrafine suspensions from the very first half of the 20th century (Pahl MH. Zerkleinerungstechnik. Cologne 1991). In the machining chamber are loaded milling plates, diffusion medium (usually water), stabilization, and product. Impact shear forces, created by the motion of the machining media, result in reducing of the particle size. Unlike higher pressure homogenisation, it is a method of small-energy-milling. The balls are composed of resin-coated polystyrene beads made from ceramics, stainless steel, and glass or closely interlaced. A significant problem of this engineering is the erosion from either the friction content during most of the milling method. The friction particles are treated to minimize the amount of contaminants induced by both the degradation of the milling media (Bruno JA *et al.,* 1992). A further issue is the new product compliance to the mill's inner surface (which consists primarily of both the milling pearl surface and the mill surface as a whole).Friction would have two main principles. If the turbulence press is pushed through such an agitator or even the whole tank is pushed in a fluid motion that contributes to the turbulence press revolution (Merisko-Liversidge E *et al.,* 2003). This approach is an interesting technology of reducing particle volume that is illustrated through the use of four FDA-approved drugs which could later be the subject of this document.

Homogenization method: There are three main developments in the production of nanocrystals using homogenization techniques: microfluidizer technology (IDD-PTMTM engineering), water piston gap homogenization (Dissocubes ® innovation).

Microfluidizers are designed to create small particles under stress of up to 1700 bar (Bruno RP *et al* 1999) by a simple head on collision of two fluid fluxes. It leads to particle collision, to tensile forces and to cavitation forces (Tunick MH *et al.,* 2002). Jet stream homogenizers including the micro fluidizer (Microfluidizer ®, Microfluidics Inc.) can achieve it. That cavity for both the collision could be developed in two versions, whether Y-type or Z-type. Fortunately, for a reasonable reduction in particle size, a relatively significant amount of loops (50 to 100 passes) is required. With its Insoluble Drug Discovery (IDD) technology, SkyePharma uses this principle to accomplish poorly soluble growth of submicron particulate matter. For addition, the Dissocubes ® method requires piston range homogenizers. SkyePharma PLC discovered a route, and bought it later(Müller RH *et al.,* 1995 and Müller RH *et al* 1999).It is processing suspensions of nanoparticles in liquid at room temperature. A product substance is spread in an aqueous surfactant mixture and then pushed by both a piston through the narrow homogenization gap through forces of up to 4000 bar, usually between 1500 and 2000 bar. The length of the homogenization gap ranges from around (Möschwitzer J 2005) 5 to 20 µm, fluctuates depending from both the viscosity of both the suspension as well as the pressure becoming introduced. The resulting high tension transmission

velocity causes an increase in kinetic pressure, which would be compensated by a decline in dynamic pressure there under aqueous dielectric constant of the system (as per Bernoulli's law).

Gas bubbles form when the water starts to boil at room temperature. These gas bubbles spontaneously burst as the liquid exits the homogenisation gap during normal air stress of 1 bar again.

This occurrence of gas bubble formation and implosion is called vortex shedding which leads to concussive blasts. Due to the strong shear forces, vigorous flow and the immense strength of these shockwaves, the product fragments are diminished in size (Muller RH 2001). Of course water usage may have drawbacks, e.g. hydrolysis of liquid-sensitive medicines and issues throughout corresponding drying steps (such as removing too much water).Hence the technique is ideally suited for formulating aqueous nanocrystal suspensions (Muller RH 2003).

The Nanopure ® process, operated and established by PharmaSol GmbH in Berlin, is yet another technique that uses the piston-gap homogeniser. The method requires low vapor pressure dispersion media, and likely homogenisation at low temperatures. The cavitation within the homogenisation distance is rather small or zero. The size decrease was acceptable even without deformation (Bushrab NF *et al.,* 2003). Nanoparticles involve the residual frictional forces, collisions with particles, and turbulences. The low temperatures necessary for manufacturing heat labile drugs when homogenizing (Müller RH *et al.,* 2002). For quasi-aqueous conditions, essentially the entire process should also be conducted to protect medicines towards hydrolysis. They can be packed immediately into gelatin or HPMC capsules using oils, PEG or hot-melted polyethylene glycols (Keck CM 2004).

Only the accompanying approaches are present in order to provide a full description of accessible technology. The organization Baxter uses a precipitation stage for its NanoEdgeTM technology by introducing high energy, e.g., highshear and/or thermal energy (Kipp JE *et al.,* 2003) with corresponding annealing phase. PharmaSol uses a pretreatment step with corresponding homogenisation in its Nanopure XP technology to generate particles far below 100 nm (Müller RH 1996; Müller RH 2005; Lee S 2005).

Nanocrystal drug product

Nanocrystals has been a subject of high technology development activity because of our high property charging performance, consistent breakdown levels, improved structural strength and extended diffusion periods. Many drugs are still on the marketplace, and human trials are also under way for a range of other products.

Nanocrystal-drug products in the market: Through 1995, the FDA has authorized ~50 nanodrugs for different applications, mainly centered on liposomes, polymers, and nanocrystals (Bobo D 2016; Caster JM 2017). Nanocrystallization is an efficient means of formulating and producing poorly soluble drugs. The technology's market appeal will be further boosted by the relatively short period period towards clinical acceptance. Although liposomes took approximately 25 years to commercialize, Emend ®'s relative graphical fidelity was just 10 years. The first patent application for Emend was submitted in 1990, and the company was released in 2000. Thus, a considerable number of nanocrystal drug products were established and successfully tested within the same short time, relative to other nanosized frameworks.

A first branded nanocrystal drug medicine, launched by Wyeth Pharmaceutical products in 2000, was Rapamune ®, a poorly soluble immunosuppressant Sirolimus (SRL). Rapamune was manufactured and use the process of pearl milling and its binding affinity in its traditional oral solution formulation was observed to be 21 per cent higher than SRL. These were followed by the creation in 2003 of Emend (Aprepitant), by Merck. Emend was formed from

Aprepitant — a moderately water-soluble pro-emetic drug that can be consumed only in the upper gastrointestinal tract and has a small absorption period.Tricor ®, which was introduced by Abbott Laboratories in 2003, was developed and use the pearl mill manufacturing method from fenofibrate— a lipophilic drug for hypercholestremia. Formulating fenofibrate into nanocrystals strengthened its insulative properties to both the gut wall and enhanced its binding affinity by 9 percent regardless of whether it is fed or fasted. It has given way for patients to provide a simpler, adjustable sublingual routine. The nanocrystal drug product inspired by fenofibrate is Triglide ®, which Skyepharma had launched in 2005.

Megace ES was made from megestrol acetate into nanocrystals–a consuming painkiller utilizing pearl milling technique. This improved its degradation frequency and decreased the single dose size by several times, thereby improving its binding affinity and user adherence with extremely aggressive megestrol acetate as compared to oral suspension.

Nanocrystal drug-products in clinical trials: Most nanocrystal medicinal properties are currently recommended for oral consumption and treatment of besides cancer diseases. The oral management market is large and, relative to injectables, the road to marketing is smoother. The process of product approval for nanocrystal product substances is easier as the content consists primarily of the pharmaceutical which can be mixed with GRAS-approved stabilisers and inert ingredients. Although there has currently been several nanocrystal drugs in clinical trials taking into consideration the feasibility of accelerated development and marketing. Cytokine Pharamsciences (CPSI) Semapimod ® nanocrystals is a synthetic guanylhydrazone and has already been observed to function as just an immunomodulator, preventing the development of TNF-α, a proinflammatory cytokine that is involved in inflammatory reaction-in cancer patients throughout a Phase I study(Home - Ferring Corporate 2018). After only a comprehensive clinical trial, CPSI also found that the drug has been effective in preventing psoriasis and Crohn's disease mild to extreme. The nanocrystal drug commonly used during clinical studies is PAXCEEDTM from Angiotech Pharmaceutical products, In.(Raghava Srivalli KM, Mishra B. 2016).PAXCEED is made of paclitaxel and is a medicinal drug free of EL cremophorus. This might greatly minimize oversensitivity in patients diagnosed with cancer or with chronic inflammation. Celmed BioSciences Inc. (Saint-Laurent, QC)'s TheraluxTM is a photodynamic counseling-based thymectacin management tool that is poorly soluble and poor bioavailability (New Biotic. 2018). Inflammatory disorders, anti-Hodgkin's lymphoma, bowel cancer and the prevention of graft-versus-host infection are presently under evaluation. Nucryst Pharmaceuticals (Wakefield, MA) established a cream composition centered on a patented NPI 32101 material that mainly consists of silver nanocrystals (Bhol KC 2004; Bhol KC 2005). The medicine exhibited encouraging antifungal and non-inflammatory properties (Lyczak J 2005). Phase II clinical trials for atopic dermatitis are due to be completed at NPI 32101. Panzem ® NCDs is developed out of 2-Methoxyestradiol (2-ME2)—a legitimate estradiol metabolite (EntreMed, Inc.). In preclinical trials, 2-ME2 displayed encouraging antiproliferative and antiangiogenic attributes. Entremed then went on with Panzem to assess her operation toward ovarian cancer, and other strong carcinomas. It could not go through Phase II nevertheless, and then all of Panzem's clinical growth was suspended (Harrison MR 2011).

Conclusion

As the descriptions has demonstrated, only with a certain slight disadvantages, nanocrystal company provides enormous benefits. This is specifically best suited for medications that have issues with solubility. Diminishment of particle size and the resulting increase in particle density, thickness, bioavailability in aggregation, and therefore the enhanced velocity of dissolution, are important factors. Improving bioavailability alone isn't the only critical factor. Whenever a medicine has a small

functional period where it could be consumed it is much more essential. The improved solubility and speed When a wide dosage is needed to maintain acceptable levels in the blood for poorly soluble drugs leading to greater side effects, the nanocrystal technology enables for smaller doses and decreased adverse effects as an implication. The drawbacks are the processing periods that are often long, e.g. in pearl milling. Nevertheless, new inventions have only been submitted to automate wide scale development, e.g., H42. Additionally, there is a need for modern technologies to manufacture tablets containing high medicine nanocrystal volumes to manufacture high-dose medicines in–preferentially–one single tablet.. For both the nanoparticles it will be an essential part of the research in particular

References

Anger S. 2005. Pharmazeutische Technologie. Berlin, Freie Universität; PhD Thesis.

Anselmo AC, Mitragotri S. 2014. An overview of clinical and commercial impact of drug delivery systems. Journal of Control Release **190,** 15-28. http://dx.doi.org/10.1016/j.jconrel.2014.03.053

Bae YH, Park K. 2011. Targeted drug delivery to tumors: myths, reality and possibility. Journal of Control Release**153,** 198-205. http://dx.doi.org/10.1016/j.jconrel.2011.06.001

Bhol KC, Alroy J, Schechter PJ. 2004. Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a Guinea pig model. Clinical and Experimental Dermatology **29,** 282-287. http://dx.doi.org/10.1111/j.1365- 2230.2004.01515.x

Bhol KC, Schechter PJ. 2005. Topical nanocrystalline silver cream inhibits expression of matrix metalloproteinase-9 in animal models of allergic contact dermatitis. The British Journal of Dermatology **152(6),** 1235-42. http://dx.doi.org/10.1111/j.1365-2133.2005.06575.x

Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. 2016. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharmaceutical Research **33**, 2373-2387. http://dx.doi.org/10.1007/s11095-016-1958-5

Boleininger J, Kurz A, Reuss V, Sönnichsen C. 2006. Microfluidic continuous flow synthesis of rod-shaped gold and silver nanocrystals. Physical Chemistry Chemical Physics **8,** 3824-3827. https://doi.org/10.1039/B604666E

Brough C, Williams RO. 2013. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. International Journal of Pharmaceutics **453,** 157-166. http://dx.doi.org/10.1016/j.ijpharm.2013.05.061

Bruno JA, Doty BD, Gustow E. 1992. Method of grinding pharmaceutical substances. US Patent 5518187; USA.

Bruno RP, McIlwrick R. 1999. Microfluidizer processor technology for high performance particle size reduction, mixing and dispersion. European Journal of Pharmaceutics and Biopharmaceutics **56,** 29–36.

Bushrab NF, Müller RH. 2003. Nanocrystals of poorly soluble drugs for oral administration. Journal of New Drugs. **5,** 20–2.

Caster JM, Patel AN, Zhang T, Wang A. 2017. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. wiley interdiscip rev nanomed nanobiotechnol journal **9,** e1416. http://dx.doi.org/10.1002/wnan.1416

Chen H, Khemtong C, Yang X, Chang X, Gao J. 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discovery Today **16,** 354-360. http://dx.doi.org/10.1016/j.drudis.2010.02.009

Chong-Hui G, Grant DJW. 2001. Estimating the

relative stability of polymorphs and hydrates from heats of solution and solubility data. Journal of Pharmaceutical Sciences **909,** 1277–87. https://doi.org/10.1002/jps.1080

Cinzia De Vita VC. 2004. Nanostructured hybrid materials from aqueous polymer dispersions. Advances in Colloid and Interface Science 108–109C, 167–85. http://dx.doi.org/10.1016/j.cis.2003.10.017

De Jong WH, Borm PJA. 2008. Drug delivery and nanoparticles: applications and hazards. International Journal of Nanomedicine **3,** 133-149. http://dx.doi.org/10.2147/ijn.s596

Gao L, Liu G, Ma J. 2013. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharmaceutical Research **30,** 307-324. http://dx.doi.org/10.1007/s11095-012-0889-z

Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. 2012. Drug nanocrystals: in vivo performances. Journal of Controlled Release **160,** 418-430. http://dx.doi.org/10.1016/j.jconrel.2012.03.013

Gassmann P, List M, Schweitzer A. 1994. Hydrosols – alternatives for the parenteral application of poorly water-soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics **40,** 64–72.

George J, Sabapathi SN. 2015. Cellulose nanocrystals: synthesis, functional properties, and applications. Nanotechnology, Science and Applications **8,** 45-54 http://dx.doi.org/10.2147/NSA.S64386.

Grau MJ. Dissertation. Pharmazeutische Technologie. Berlin: Freie Universität; 2000. Untersuchungen zur Lösungsgeschwindigkeit, Sättigungslöslichkeit und Stabilität von hochdispersen Arzneistoffsuspensionen.

Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharmaceutical Research **174,** 397–404 http://dx.doi.org/10.1023/a:1007516718.048

Harrison MR, Hahn NM, Pili R. 2011. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs **29,** 1465-1474. http://dx.doi.org/10.1007/s10637-010-9455-x

He Y, Xia DN, Li QX, Tao JS, Gan Y, Wang C. 2015. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation. Acta Pharmacologia Sinica **36,** 1151-1160 http://dx.doi.org/10.1038/aps.2015.53.

Junghanns J, Müller R. 2008. Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicine **3(3),** 295-309.

Kalepu S, Nekkanti V. 2015. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharma Sinica B **5,** 442-453. https://doi.org/10.1016/j.apsb.2015.07.003

Kanellos M. Moore says nanoelectronics face tough challenges. CNet News. 2005. [online]. 9 March. url

Kazimierski P, Alexander. Von Humboldt Foundation Conference 2005. Piotr: Alexander von Humboldt Foundation; Nanotechnology for medicine.

Keck CM, Bushrab NF, Müller RH. Nanopure® nanocrystals for oral delivery of poorly soluble drugs. Particles; April 20–23, 2002; Orlando, Florida, USA. 2004.

Kipp JE, Wong JCT, Doty MJ, Microprecipitation method for preparing submicron suspensions. US Patent 6607784; USA: 2003.

Koshani R, Madadlou AA 2018. Viewpoint on the gastrointestinal fate of cellulose nanocrystals. Trends in Food Science & Technology **71**, 268-273. https://doi.org/10.1016/j.tifs.2017.10.023

Kreuter J, Alyautdin RN, Kharkevich DA. 1995. Passage of peptides through the blood – brain barrier with colloidal polymer particles nanoparticles. Brain Research **674(1),** 171–4. http://dx.doi.org/10.1016/0006-8993(95)00023-j

Lee BK, Yun YH, Park K. 2015. Smart nanoparticles for drug delivery: boundaries and opportunities. Chemistry of Engineering and Science **125,** 158-164. http://dx.doi.org/10.1016/j.ces.2014.06.042

Lee S, Nam K, Kim MS. 2005. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Archieves of Pharmacia Research **287,** 866–74.

List MA, Sucker H. Pat No. GB 2200048. Great Britian: 1988.

Lu PS, Inbaraj BS, Chen BH. 2018. Determination of oral bioavailability of curcuminoid dispersions and nanoemulsions prepared from Curcuma longa Linnaeus. Journal of the Science of Food and Agriculture **98,** 51-63. http://dx.doi.org/10.1002/jsfa.8437

Lu Y, Chen Y, Gemeinhart RA, Wu W, Li T. 2015. Developing nanocrystals for cancer treatment. Nanomedicine. **10,** 2537-2552. http://dx.doi.org/10.1002/jsfa.8437

Lu Y, Li Y, Wu W. 2016. Injected nanocrystals for targeted drug delivery. Acta Pharma Sinica B **6,** 106-113. http://dx.doi.org/10.1016/j.apsb.2015.11.005

Lu Y, Qi J, Dong X, Zhao W, Wu W. 2017. The in vivo fate of nanocrystals. Drug Discovery Today **22,** 744-750. http://dx.doi.org/10.1016/j.drudis.2017.01.003

Lyczak J, Schechter P. 2005. Nanocrystalline silver inhibits antibiotic-, antiseptic-resistant bacteria. American Society for Clinical Pharmacology and Therapeutics **77,** P60-P60. https://doi.org/10.1016/j.clpt.2004.12.119

Malamatari M. 2018. Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discovery Today. **23,** 534-547. http://dx.doi.org/10.1016/J.DRUDIS. 2018. 01.016.

Maudens P, Seemayer CA, Thauvin C, Gabay C, Jordan O, Allémann E. 2018. Nanocrystal-polymer particles: extended delivery carriers for osteoarthritis treatment. Small **14.** http://dx.doi.org/170310810.1002/smll.201703108.

Merisko-Liversidge E, Liversidge GG, Copper ER. 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. European Journal of Pharmaceutical Sciences **18,** 113–20. http://dx.doi.org/10.1016/s0928-0987(02)00251-8

Merisko-Liversidge E, Liversidge GG. 2011. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Advanced Drug Delivery Reviews **63,** 427-440. http://dx.doi.org/10.1016/j.addr.2010.12.007

Merisko-Liversidge E. 2002. Nanocrystals: Resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. Particles; April 20–23, Orlando, Florida, USA.

Merkle RC. 1999. Biotechnology as a route to nanotechnology. Trends in Biotechnology **17,** 271-4 http://dx.doi.org/10.1016/s0167-7799(99)01335-9

Miao X, Yang W, Feng T, Lin J, Huang P. 2017.

Drug nanocrystals for cancer therapy. Wiley Interdisciplinary Reviews Nanomedicine and Nano biotechnology **10,** e1499 http://dx.doi.org/10.1002/wnan.1499.

Möschwitzer J. Pharmazeutische Technologie. Freie Universität; Berlin: 2005. PhD Thesis (in preparation)

Möschwitzer JP, Müller RH. 2013. Factors influencing the release kinetics of drug nanocrystal-loaded pellet formulations. Drug Development and Industrial Pharmacy **39,** 762-769. https://doi.org/10.3109/03639045.2012.702347

Möschwitzer JP. 2013. Drug nanocrystals in the commercial pharmaceutical development process. International Journal of Pharmaceutics **453,** 142-156. http://dx.doi.org/10.1016/j.ijpharm.2012.09.034

Müller BW, Bleich J. 1996. Production of drug loaded microparticles by the use of supercritical gases with the Aerosol Solvent Extraction System (ASES) process. Journal of Microencapsulation **132,** 131–9. http://dx.doi.org/10.3109/0265204960 9052902

Müller RH, Becker R, Kruss B. 1999.Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. US Patent 5858410; USA:

Müller RH, Jacobs C, Kayser O. 2003. DissoCubes – a novel formulation for poorly soluble and poorly bioavailable drugs. In: Rathbone MJ, Hadgraft J, Roberts MS, editors. Modified-release drug delivery systems. New York: Marcel Dekker; p. 135–49.

Muller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Advanced Drug Delivery Reviews. **471,** 3–19. http://dx.doi.org/10.1016/s0169-409x(00)00118-6

Muller RH, Keck CM. 2004. Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. Journal pf Biotechnology **113,** 151-170. http://dx.doi.org/10.1016/j.jbiotec.2004.06.007

Müller RH, Lück M, Kreuter J. Arzneistofträgerpartikel für die gewebsspezifische Arzneistoffapplikation. Germany: 1998. PCT/EP98/06429.

Müller RH, Möschwitzer JP. 2005. Method and apparatus for the production of ultrafine particles and coating of such particles. German 53 862.2 Application.

Müller RH, Pardeike J, Hommoss A. Nanoparticles in therapeutics: drug nanocrystals and lipid nanoparticles. MSTI-Congress NanoTrends 2006; Berlin, Germany.

Müller RH, Peters K, Becker R. 1995. Nanosuspensions – a novel formulation for the IV administration of poorly soluble drugs. 1st World Meeting of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; Budapest.

Müller RH. 2002. Nanopure technology for the production of drug nanocrystals and polymeric particles. 4th World Meeting of the Italian Association of Professors and Academic Researchers of Pharmaceutics, Pharmaceutical Technology, Biopharmaceutics and Regulatory Affairs; Florence, Italy.

Mura S, Nicolas J, Couvreur P. 2013. Stimuli-responsive nanocarriers for drug delivery. Nature Materials. **12,** 991-1003. New Biotic. Accessed December **19,** 2018. https://doi.org/10.1038/nmat3776 https://www.newbiotic.com/

Noyes A, Whitney W. 1897. The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society. **19,** 930–4 http://dx.doi.org/10.1021/ja02086a003

Pahl MH. Zerkleinerungstechnik. Cologne: TÜV Rheinland GmbH; 1991.

Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. 2014 Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. Journal of Controlled Release **183,** 51-66. http://dx.doi.org/10.1016/j.jconrel.2014.03.030

Peltonen L, Hirvonen J. Drug nanocrystals–versatile option for formulation of poorly soluble materials. International Journal of Pharmaceutics **537,** 73-83. http://dx.doi.org/10.1016/j.ijpharm.2017.12.005

Peltonen L, Hirvonen J. 2010. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. Journal of Pharmacy and Pharmacology **62,** 1569-1579. http://dx.doi.org/10.1111/j.2042-7158. 2010.01022.x

Raghava Srivalli KM, Mioshra B. 2016. Drug nanocrystals: A way toward scale-up. Saudi Pharmaceutical Journal **24(4),** 386-404. http://dx.doi.org/10.1016/j.jsps.2014.04.007

Savjani KT, Gajjar AK, Savjani JK. 2012. Drug solubility: importance and enhancement techniques. ISRN Pharmacology. **012,** 195727 https://doi.org/10.5402/2012/195727

Shackleford DM, Faassen WA, Houwing N. 2003. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. Journal of Pharmacology and Experimental Therapeutics **306(3),** 925–33. http://dx.doi.org/10.1124/jpet.103.052522

Shegokar R, Müller RH. 2010. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. International Journal of Pharmaceutics **399,** 129-139. http://dx.doi.org/10.1016/j.ijpharm.2010.07.044

Sonvico F, Mornet S, Vasseur S. 2005. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chemistry **16,** 1181-1188. http://dx.doi.org/10.1021/BC050050Z.

Speiser PP. 1998. Poorly soluble drugs: a challenge in drug delivery. In: Müller RH, Benita S, Böhm B, editors. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Medpharm Stuttgart: Scientific Publishers; p 15–28

Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. 2018. Potential applications and human biosafety of nanomaterials used in nanomedicine. Journal of Applied Toxicology **38,** 3-24. http://dx.doi.org/10.1002/jat.3476

Tunick MH, Van Hecken DL, Cooke PH, *et al.* 2002. Transmission electron microscopy of mozzarella cheeses made from microfluidized milk. Journal of Agriculture and Food Chemistry **50,** 99–103. http://dx.doi.org/10.1021/jf010633c

Tuomela A, Saarinen J, Strachan CJ, Hirvonen J. 2016. Production, applications and in vivo fate of drug nanocrystals. Journal of Drug Delivery Science and Technology **34,** 21-31. https://doi.org/10.1016/j.jddst.2016.02.006

US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. 2017. Waiver of in vivo bioavailability and

bioequivalence studies for immediate-release solid Oral dosage forms based on a biopharmaceutics classification system guidance for industry. Biopharmaceutics. 1-19.

Van Eerdenbrugh B, Van den Mooter G, Augustijns P. 2008. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. International Journal of Pharmaceutics **364,** 64-75.
https://doi.org/10.1016/j.ijpharm.2008.07.023

Velikov K. Colloidal delivery systems for functional food design. 9th Annual NSTI Nanotechnology Conference and Trade Show, Nanotechnology 2006; Boston, Massachusetts, USA. 2006.

Wang X, Zhuang J, Peng Q, Li Y. A 2005. General strategy for nanocrystal synthesis. Nature **437,** 121-124
https://doi.org/10.1038/nature03968

Willems L, Van der Geest R, de Beule K. 2001. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. Journal of Clinical therapeutics and Pharmcy **26,** 159–61
https://doi.org/10.1046/j.1365-2710.2001.00338.x